Every 10-Q that Bluejay Diagnostics, Inc. (BJDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BJDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BJDX filings page.
Bluejay Diagnostics, Inc. is a development‑stage medical diagnostics company advancing its Symphony platform and first IL‑6 test for sepsis, with clinical and regulatory efforts focused on supporting a planned 510(k) submission to the FDA, currently targeted for the first half of 2027, subject to successful analytical and clinical validation.
For the six months ended June 30, 2026, the company reported a net loss of $4,243,254, compared with $3,821,039 a year earlier, driven mainly by higher clinical development spending; research and development expenses were $2,249,643 and general and administrative expenses were $2,038,312.
Cash and cash equivalents were $9,598,916 and current liabilities were $2,116,641 as of June 30, 2026, with an accumulated deficit of $45,760,521 and negative operating cash flow of $3,088,556 for the six‑month period, leading management to state that substantial doubt exists about its ability to continue as a going concern. The company raised gross proceeds of approximately $8.5 million in a June 2026 private placement and $125,000 in a March 2026 insider financing, and estimates existing cash will fund operations through the second quarter of 2027 while it seeks an additional $10.0–$14.0 million of capital and works to maintain Nasdaq listing compliance.
Bluejay Diagnostics, Inc. reported a net loss of $1.9 million for the quarter ended March 31, 2026, similar to the prior year, with operating expenses of about $1.9 million split between research and development and general and administrative costs.
The company ended the quarter with $3.7 million in cash and cash equivalents and current liabilities of $1.4 million, and estimates its cash will fund operations only through the third quarter of 2026. Management discloses substantial doubt about its ability to continue as a going concern and expects to need at least $20 million in additional capital by the end of 2027 to pursue FDA clearance of its Symphony IL‑6 sepsis test.
Bluejay continues a pivotal SYMON‑II sepsis study and cartridge manufacturing work with contract manufacturer Sanyoseiko, but notes that failure to secure financing could force it to delay or abandon its regulatory strategy and potentially pursue liquidation, in which common stockholders may recover little value.
Bluejay Diagnostics filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $1,597,632 for the quarter and $5,418,671 for the nine-month period. Operating expenses were $1,616,947 in the quarter, led by research and development of $785,608 and general and administrative of $831,339.
Cash and cash equivalents were $3,082,268 with current liabilities of $1,148,913, and accumulated deficit reached $40,087,455. Management states that these results, combined with expected negative cash flows, raise substantial doubt about the company’s ability to continue as a going concern. A private placement in October 2025 generated ~$4.5 million gross proceeds, and the company estimates its cash resources can fund operations into the third quarter of 2026.
Bluejay continues developing its Symphony IL-6 test for sepsis, advancing the SYMON-II pivotal study with approximately half of the targeted enrollment achieved by quarter-end. The company expects to need to raise at least $20 million through 2027 to complete manufacturing redevelopment, clinical work, and prepare a 510(k) submission targeted for 2027.